Device Trial Radar · NCT06685848
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 29, 2024
Primary completion
May 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- HemanextNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021 and marketing authorization through the FDA De Novo process in September 2023.
Conditions
- Hematologic Neoplasms
Interventions
Hemanext ONE systemDevice
Hypoxic red blood cells
Conventional RBCsDevice
Conventional manufactured Red blood cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of RBCs units per unit of timeTime frame: Through study completion, an average of 15 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Duke University Health System
Durham, North Carolina
Haukeland University Hospital
Bergen, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.